My watch list  

12 Current news about the topic diabetic foot ulcers


You can refine your search further. Select from the filter options on the left to narrow down your results.

Topical gel made from oral blood pressure drugs shown effective in healing chronic wounds


An international team of researchers led by Johns Hopkins has shown that a topical gel made from a class of common blood pressure pills that block inflammation pathways speeds the healing of chronic skin wounds in mice and pigs. A report of the findings marks efforts to seek approval from the ...


image description
Skin cells 'crawl' together

Healing wounds treated with unique hydrogel layer


Time may not heal all wounds, but a proprietary mix of peptides and gel developed by U of T Engineering researchers heals most. A team led by Professor Milica Radisic has demonstrated for the first time that their peptide-hydrogel biomaterial prompts skin cells to "crawl" toward one another, ...


Avita Medical Initiates European Trial Using ReCell In the Management of Chronic Lower Limb Ulcers


Avita Medical Ltd. has initiated a multicenter randomized control study on the use of ReCell® Spray-On Skin® in the treatment of venous leg ulcers. Up to five European centres from countries including the United Kingdom, Germany, France and Denmark will participate in the study.Lower limb ulcers ...


Adocia reports positive phase II clinical results for the treatment of diabetic foot ulcer


Adocia announced positive results from its Phase II clinical trial evaluating the safety and efficacy of BioChaperone(R) combined with PDGF-BB for the treatment of diabetic foot ulcer. This product has been compared with Regranex(R), a commercially available hydrogel of PDGF-BB (HealthPoint, ...


Sorbus Pharmaceuticals GmbH incorporated in Vienna, Austria


Sorbus Pharmaceuticals GmbH announced its incorporation in Vienna, Austria. Sorbus discovers and develops novel treatments for complicated wounds, cancer and other life-threatening diseases. Its lead drug, SertaSil, has demonstrated exceptional effects in patients with acute and chronic wounds ...


Biotec Pharmacon: Phase III results with SBG for diabetic foot ulcer not positive


Biotec Pharmacon has received the results from both its phase III studies with SBG for diabetic foot ulcer and regrets to inform that the results are not positive. The studies failed to show superiority of SBG vs. placebo in terms of ulcer healing, and the company will thus not proceed with the ...


Kuros starts Phase IIb clinical trial with KUR-211 for diabetic foot ulcers


Kuros Biosurgery AG announced that it has treated the first patient in a Phase IIb clinical trial investigating KUR­211 (Viz.I-020201) in the treatment of diabetic foot ulcers. KUR-211 consists of a modified variant of platelet-derived growth factor (PDGF) incorporated into a fibrin sealant and ...


Biotec Pharmacon: Phase III diabetic ulcer program proceeds as planned after interim analysis


The independent statistician responsible for the interim analysis of the second of the two phase III studies with SBG for diabetic foot ulcers recommends that Biotec Pharmacon proceeds as planned with the study. As no adjustments are being made to sample size, patient enrolment is already ...


GPC Biotech and Agennix Announce Proposed Merger

Pipeline to include novel oncology therapy, talactoferrin, which recently entered Phase 3 clinical testing


GPC Biotech AG and Agennix, Incorporated announced that the two oncology-focused biotechnology companies have signed a Business Combination Agreement under which they propose to merge their businesses. In the transaction, GPC Biotech is to be merged onto a new German company, which will hold ...


CytRx Corporation Completes Acquisition of Innovive Pharmaceuticals, Inc.

Near-Term Commercialization Opportunities from Innovive’s Oncology Portfolio Complement CytRx Molecular Chaperone Pipeline and Technology Platform


CytRx Corporation announced the completion of its acquisition of Innovive Pharmaceuticals, Inc. CytRx purchased Innovive for total consideration of approximately 2.6 million shares of CytRx common stock, approximately $18.3 million of future performance-based milestone earn-outs, and the ...


Page 1 From 2
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE